Patients with severe asthma who initiate biologics may reduce their risk for oral corticosteroids (OCS)-related new-onset adverse outcomes.

Increased risk for all-cause and CVD mortality in OSA may be linked to a severe phenotype marked by objective excessive daytime sleepiness.

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

The FDA published over 200 response letters sent as replies to drug and biological product applications in order to increase transparency.